We are proud to welcome PKDerm as GARD® distributor.
Located in Grasse, France, PKDerm offers innovative in vitro solutions to pharmaceutical, dermo-cosmetic and chemical industries in order to evaluate the efficacy and safety of products likely to come into contact with the skin.
“As a GARD distributor, we are excited to offer a solution to customers in various industries for their in vitro testing needs. GARD has shown impressive performance in skin sensitization, and its ability to evaluate a large variety of substances combined with potency measurement makes it truly unique. We expect the GARD assays to become an essential complement to our portfolio”, says Hanan Osman-Ponchet, PKDerm’s founder and CEO.
Hanan Osman-Ponchet, PKDerm’s founder and CEO.
We are excited to announce that another CRO has been fully trained on SenzaGen’s GARD technology platform and is offering GARDskin and GARDair services.
As a leading provider of in vitro toxicity testing to the US and worldwide, MB Research Labs is deeply committed to their customers and is dedicated to offering the latest predictive and innovative test methods.
We are delighted to have MB Research Laboratories in our partner network.
Dr. George DeGeorge and Dr. Michelle Cicchini of MB Research Laboratories performing the GARD assay.
Toxicological Sciences, kfz108, https://doi.org/10.1093/toxsci/kfz108
Henrik Johansson, Robin Gradin, Angelica Johansson, Els Adriaens, Amber Edwards, Veronika Zuckerstätter, Anders Jerre, Florence Burleson, Helge Gehrke, Erwin Roggen
Proactive identification of chemicals with skin sensitizing properties is a key toxicological endpoint within chemical safety assessment, as required by legislation for registration of chemicals. In order to meet demands of increased animal welfare and facilitate increased testing efficiency also in non-regulatory settings, considerable efforts have been made to develop non-animal approaches to replace current animal testing.
GARD™, GARD™skin, in vitro, sensitization, chemical sensitizers
Article on line ahead of print with open access
One of Sweden’s most famous influencers, Margaux Dietz, has visited SenzaGen in Lund.
With support from the EU, SenzaGen has developed the world’s first animal-free test for respiratory allergies making our daily products safer. Margaux put a lab coat on and got to allergy test her own shampoo. Now, Margaux knows that the EU investments in innovations make a difference in everyday life.
Wiley Online Library, First published: 21 April 2019, https://doi.org/10.1111/cod.13294.
Renato I. de Ávila Danillo F. M. C. Veloso Gabriel C. Teixeira Thaisângela L. Rodrigues Tim Lindberg Malin Lindstedt Simone G. Fonseca Eliana M. Lima Marize C. Valadares
Allergic contact dermatitis reported to henna‐based hair coloring products (HPs) has been associated with adulteration of henna with p‐phenylenediamine (PPD).
To develop a testing approach based on in vitro techniques that address key events within the skin sensitization adverse outcome pathway to evaluate allergenic potential of HPs.
The following in vitro assays were used to test the sensitizing capacity of hair dye ingredients: micro‐direct peptide reactivity assay (mDPRA); HaCaT keratinocytes‐associated IL‐18 assay; U937 cell line activation test (USENS)/IL‐8 levels; blood monocyte‐derived dendritic cell test; genomic allergen rapid detection (GARD skin). Those techniques with better human concordance were selected to evaluate the allergenic potential of ten HPs.
Contrasting to the label’s information, chromatographic analyses identified PPD in all products. The main henna biomarker, lawsone, was not detected in one of 10 the products. Among the techniques evaluated by testing HDIs, mDPRA, IL‐18 assay, GARD skin and U‐SENS correlated better with human classification (concordances 91.7 to 100%) and were superior to the animal testing (concordance 78.5%). Thus, these assays were used to evaluate HPs, which were classified as skin sensitizers using different two‐out‐of‐three approaches.
Our findings highlight toxicological consequences and risks associated of the undisclosed use of PPD in henna‐based “natural” “real‐life” products.
This article is protected by copyright. All rights reserved.
To replace a test animal, which is clearly a complex system with blood and organs, you need a more holistic approach to model the entire allergic response within the body. Our CEO Anki Malmborg Hager explains the benefits of using alternative testing methods to prove product safety in this week’s Manufacturing Chemist.
Int. J. Mol. Sci. 2019, 20(3), 666; https://doi.org/10.3390/ijms20030666
Gunilla Grundström and Carl A.K. Borrebaeck
There is an increasing demand for alternative in vitro methods to replace animal testing, and, to succeed, new methods are required to be at least as accurate as existing in vivo tests. However, skin sensitization is a complex process requiring coordinated and tightly regulated interactions between a variety of cells and molecules. Consequently, there is considerable difficulty in reproducing this level of biological complexity in vitro, and as a result the development of non-animal methods has posed a major challenge. However, with the use of a relevant biological system, the high information content of whole genome expression, and comprehensive bioinformatics, assays for most complex biological processes can be achieved. We propose that the Genomic Allergen Rapid Detection (GARD™) assay, developed to create a holistic data-driven in vitro model with high informational content, could be such an example. Based on the genomic expression of a mature human dendritic cell line and state-of-the-art machine learning techniques, GARD™ can today accurately predict skin sensitizers and correctly categorize skin sensitizing potency. Consequently, by utilizing advanced processing tools in combination with high information genomic or proteomic data, we can take the next step toward alternative methods with the same predictive accuracy as today’s in vivo methods—and beyond.
On December 4-5, SenzaGen was attending BioFIT in Lille, France. BioFIT is a business development meeting with focus on early stage innovations including pre-clinical stage assets. We met with CROs and life science companies from all over Europe in search of screening tools at pre-clinical stage. Read more about Biofit here: https://www.biofit-event.com